Feasibility Study of Neoadjuvant Olaparib for Frontline BRCA Mutant Ovarian Cancer

Authors

• Victoria Michael, McGovern Medical SchoolFollow
• Shannon N. Westin, The University of Texas MD Anderson Cancer Center
• Michaela Onstad-Grinsfelder, The University of Texas MD Anderson Cancer Center
• Larissa A. Meyer, The University of Texas MD Anderson Cancer Center
• Nicole Fleming, The University of Texas MD Anderson Cancer Center
• Yin Yuan, The University of Texas MD Anderson Cancer Center

Files

DOI

https://doi.org/10.52519/00018

Keywords

Olaparib; Neoadjuvant; BRCA Mutation

Program Affiliation

Partnership for Careers in Cancer Science and Medicine

Recommended Citation

Michael, Victoria; Westin, Shannon N.; Onstad-Grinsfelder, Michaela; Meyer, Larissa A.; Fleming, Nicole; and Yuan, Yin, "Feasibility Study of Neoadjuvant Olaparib for Frontline BRCA Mutant Ovarian Cancer" (2022). Summer Experience 2022. 93.
doi:https://doi.org/10.52519/00018